Skip to content

Oruka Therapeutics, Inc.

ORKA

CIK 0000907654

← back to feed
Revenue (TTM)
$0
Q1 Apr 2026
Net Income (TTM)
−$107.67M
−25.9% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$9.28
−945.9% YoY Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
—
Q1 Apr 2026
Net Margin
—
Q1 Apr 2026
Free Cash Flow (TTM)
−$47.66M
Q1 Apr 2026
Cash
$49.52M
Q1 Apr 2026
Total Debt
—
Q1 Apr 2026
Shares Outstanding
60.31M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings